|
 |
|
Amersham Pharmacia Biotech
Amersham Pharmacia Biotech is a leading global provider of biotechnology systems, products and services used in gene and protein research, drug discovery and development, and biopharmaceutical manufacture. Our vision is to deliver technologies that make molecular medicine possible.
Under the Ettan brand, meaning 'first' in Swedish, we have built on our significant experience in protein analysis, separation and purification to develop new systems for protein research.
Some of our proteomics products include:
- 2D DIGE (Two Dimensional Difference Gel Electrophoresis) system
- IPGphor first dimension (IEF) system
- Ettan™ Dalt II 2D electrophoresis system
- Ettan Spot Picker to automatically pick protein spots from gels
- Ettan MALDI-TOF for mass spectrometry
|
|
 |
|
Applied Biosystems
Applied Biosystems is the leading supplier of life science technologies. We develop, market and support systems consisting of instruments, reagents and software that are used in basic life science research, pharmaceutical research and development, diagnostics, forensics and food testing.
In addition to the high-throughput capabilities of MALDI, and advanced mass spectrometry technology, Applied Biosystems provides leading-edge tools for proteomics, and other advanced methods for the separation, purification, analysis and synthesis of biomolecules, as well as innovative technologies for genetic analysis, data management, assay development and high-throughput-screening, so reducing the time and costs in the drug discovery and development process.
Our recent innovations include the next generation of novel tools for proteomics. Products include the Proteomics Solution 1™ System, the API QSTAR™ Pulsar Hybrid LC/MS/MS System, the oMALDI™ ionization source for MS/MS, ICAT™ reagents, and the Rapid Integration Solution for proteomics.
|
|
 |
|
Ciphergen
Ciphergen's new ProteinChip® Biomarker System* enables clinical researchers to rapidly discover, characterize and validate predictive protein biomarkers and biomarker patterns, right in their own lab. Clinical researchers can profile crude samples with ProteinChip Arrays, classify patients and develop predictive disease models with Biomarker Patterns* Software and generate accurate results quickly with ProteinChip Kits from Ciphergen.
Ciphergen's new ProteinChip interface to high-end quadrupole tandem MS enables basic researchers to conduct high performance protein identification, epitope mapping and protein interaction analysis for drug discovery and development. Basic researchers can now take a single drop of crude sample-that has been screened and validated 'on-chip'-directly to the ProteinChip-Tandem MS for peptide fragmentation-based sequence analysis.
Ciphergen's Technology
|
|
 |
|
GeneBio : The Innovative Biological Knowledge Company
Founded in 1997, Geneva Bioinformatics (GeneBio) S. A. is a privately held company based in Geneva, Switzerland.
GeneBio is committed to providing its clients with high quality proteomics databases, software tools and services through both in house development and strategic alliances with key research institutions and companies.
In 1998, GeneBio was named exclusive commercial representative of the Swiss Institute of Bioinformatics (SIB), offering commercial entities annual subscription to proteomics databases like SWISS-PROT, PROSITE and SWISS-2D PAGE.
Since then, GeneBio’s product range has widened to include Melanie, the prominent 2D gel analysis software developed by the SIB, GlycoSuite DB, a curated database of glycan structures developed and maintained by Proteome Systems Ltd., as well as its own bioinformatics training courses.
GeneBio’s continuing mission is to offer its clients high quality knowledge-oriented discovery tools and solutions to further enhance proteomics-based research.
|
|
 |
|
THE GENEPROT DIFFERENCE
GeneProt brings together the leading experts in proteomics and bioinformatics to solve unmet medical needs by accelerating therapeutic drug discovery and improving its quality. In April 2001, GeneProt opened the world’s first large-scale proteomic discovery and production facility in Geneva, Switzerland. Equipped with 51 state-of-the-art mass spectrometers and some of the most advanced bioinformatic and computing data-storage technologies, GeneProt will identify and, when appropriate, synthesize commercially viable novel therapeutics proteins, drug targets and biomarkers.
GeneProt’s approach uses very high throughput processes designed or improved by the company’s founders, many of whom hold patents in the fields of mass spectrometry and protein chemistry. GeneProt’s goal is to significantly shorten the time required from discovery of potentially medically important proteins to commercialization of novel therapeutic agents using a technology combination that is comprehensive, highly-automated and supported by supercomputing power.
GeneProt’s strategy focuses exclusively on achievable solutions by selecting and producing those therapeutic breakthroughs with the highest commercial potential. GeneProt expects to bring these solutions to market well in advance of competitors by implementing its unique technology package that includes massively parallel, high-throughput processing using advanced electrophoresis and mass spectrometry, and commercial and proprietary bioinformatic software and algorithms.
The company’s initial focus on the identification of small proteins, potentially active protein fragments and post-translational modifications, should enable GeneProt to deliver material for clinical trials within months, instead of years as projected by other organizations.
GeneProt is funded solely by its partners and by leading institutional investors who share the company’s long-term commitment to the development and advancement of the field of proteomics.
PROTEOMICS MARKET OPPORTUNITIES
The market potential for therapeutic proteins, such as insulin and EPO, is growing exponentially. Currently, therapeutic proteins represent some of the most lucrative drugs on the market, with estimated 1999 worldwide sales in excess of $17 billion. GeneProt is uniquely positioned to capture a significant portion of this exploding market by expanding the use of protein-based biomarkers as diagnostic tools and assisting in the development and advancement of new drug therapies.
Swiss branch:
GeneProt, Inc.
2 Pré-de-la-Fontaine
1217 Meyrin-Geneva
Switzerland
Headquarters:
GeneProt, Inc.
Technology Center of New Jersey
671 Highway One
North Brunswick, NJ 08902
USA
www.geneprot.com
|
|
 |
|
Micromass® ...The Mass Spectrometry People
Micromass® is the leading enterprise in the world solely dedicated to mass spectrometry (MS). Micromass has become the preferred supplier of high performance MS instruments and Mass-Informatics systems to the health and life science sectors because of its innovative culture, award winning technology and commitment to service.
Mass Spectrometry (MS) is a key enabling technique in analytical science. MS allows chemical entities such as priority pollutants, drugs of abuse, ethical pharmaceuticals and functional proteins to be identified and characterised by exactly measuring their molecular masses.
Micromass is a division of Waters Corporation (www.waters.com) the international market leader in high performance liquid chromatography (HPLC) - one of the leading analytical systems enterprises of the world with annual sales approaching $1 billion.
Analytical chemists and biochemists in the world’s leading scientific corporations and research institutions use Micromass’ products. Micromass, Waters and our strategic life science partner Bio-Rad Laboratories (www.biorad.com) are accelerating the pace of analysis in the environmental, geological, health, life and post-genomic sciences - with an unmatched portfolio of integrated tools and technologies.
|
|
 |
|
Nonlinear Dynamics is a leading software development company providing Bioinformatics solutions. The company provides products for in-depth analysis of 1D and 2D electrophoresis gels and microarrays, and sophisticated interrogation and integration of the resultant data. Nonlinear Dynamics boasts a customer base of over 5,000 of the leading pharmaceutical and biotechnology companies, research institutes and academic institutions.
From this strong position we have created “Nonlinear Technology”, a development resource from which a revolutionary new range of Bioinformatics products are emerging to keep researchers at the forefront of high-throughput proteomics. Progenesis will smash the proteomics analysis bottleneck, Progenera assimilates the subsequent explosion of available data and integrates this with other biodata to create truly meaningful results and Accelerator will scale each solution to a user’s needs. With the dawn of these Bioinformatics solutions, you can fully realise the potential of your Proteomics projects.
|
|
 |
|
PerkinElmer : Proteomics Precisely
PerkinElmer began in proteomics through strategic alliance with Genomic Solutions for instrumentation which automates the manual steps of classical proteomics (Gels to MS).
Key strategic areas today are:
- Proteomic Mass Spectrometry (JV with MDS Sciex)
- Proteomic Imaging: building on ProXPRESS with proprietary chemistries
- Proteoinformatics
- Alternatives to 2D gels
Recently we announced partnership with Nonlinear Dynamics: Progenesis 2D analysis software ensures customers running over 15 gels/week make enormous savings in time and costs.
We are the exponents of live cell proteomics using UltraVIEW LCI for studying target validation, protein-protein interactions in complexes, and movements within cellular compartments.
http://lifesciences.perkinelmer.com/areas/proteomics/
|
|
|
|
